Cellectis SA (CLLS)
3.73
+0.24
(+6.88%)
USD |
NASDAQ |
Feb 13, 09:48
Cellectis Cash from Investing (Quarterly) : -3.266M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| EDAP TMS SA | -1.129M |
| DBV Technologies SA | -0.2404M |
| Ascendis Pharma A/S | -3.873M |
| Akari Therapeutics Plc | 0.00 |
| Biodexa Pharmaceuticals Plc | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.627M |
| Cash from Financing (Quarterly) | -4.089M |
| Free Cash Flow | -34.73M |
| Free Cash Flow Per Share (Quarterly) | -0.0391 |
| Free Cash Flow to Equity (Quarterly) | -9.372M |
| Free Cash Flow to Firm (Quarterly) | -4.857M |
| Free Cash Flow Yield | -9.95% |